NCT06577090 - Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

January 31, 2026

Conditions

Obesity

Interventions

BIOLOGICAL

Nimacimab injection

Nimacimab injection 200 mg

BIOLOGICAL

Nimacimab placebo injection

matching nimacimab placebo injection

COMBINATION_PRODUCT

semaglutide injection

semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg

Trial Locations (16)

11375

Weill Cornell Medicine, New York

22911

Charlottesville Medical Research, Charlottesville

28401

Accellacare of Wilmington, Wilmington

30342

ACCEL Research Sites, Atlanta

30501

Center for Advanced Research & Education, Gainesville

36207

Pinnacle Research Group, Anniston

40213

L-MARC Research Center, Louisville

58104

Lillestol Research, LLC, Fargo

68516

Be Well Clinical Studies, Lincoln

75230

Velocity Clinical Research, Dallas, Dallas

78681

Be Well Clinical Studies, Round Rock

89148

Palm Research Center, Las Vegas

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Renton

06708

Chase Medical Research, LLC, Waterbury

03801

ActivMed Practices & Research, Portsmouth

All Listed Sponsors

lead

Skye Bioscience, Inc.

INDUSTRY